Reportable Segments

3 Months Ended

Oct. 31, 2020

Segment Reporting [Abstract]

Reportable Segments

Reportable Segments

In accordance with ASC Topic 280, “Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and income from operations.

Our reportable segments are as follows:

Medical: designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. Our products include endoscope reprocessing and endoscopy procedure products.

Life Sciences: designs, develops, manufactures, sells, and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. We also provide filtration/separation and disinfectant technologies to the medical and life science markets through a worldwide distributor network. Two customers collectively accounted for approximately 48.3% and 45.7% of our Life Sciences segment net sales for the three months ended October 31, 2020 and 2019, respectively.

Dental: designs, manufactures, sells, supplies and distributes a broad selection of products used by the global dental profession comprising a complete circle of protection. Our products include hand and powered dental instruments, infection control products, personal protective equipment (PPE) and water quality products for the dental suite. Three customers collectively accounted for approximately 41.2% and 43.5% of our Dental segment net sales for the three months ended October 31, 2020 and 2019, respectively.

Dialysis: designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers (a device serving as an artificial kidney), as well as dialysate concentrates and supplies utilized for renal dialysis. Three customers accounted for approximately 50.8% and 46.1% of our Dialysis segment net sales for the three months ended October 31, 2020 and 2019, respectively. These customers include one of the top two customers noted above under our Life Sciences segment.

No customer accounted for 10% or more of our consolidated net sales for the three months ended October 31, 2020 and 2019.

Information as to reportable segments is summarized below

	Three Months Ended October 31,
Net sales	2020		2019
Medical	$	132,319	$	133,353
Life Sciences	45,568		49,141
Dental	111,006		67,243
Dialysis	8,136		7,509
Total net sales	$	297,029	$	257,246

	Three Months Ended October 31,
Income from operations	2020		2019
Medical	$	26,716	$	21,119
Life Sciences	8,075		7,135
Dental	25,307		5,004
Dialysis	2,566		1,622
	62,664		34,880
General corporate expenses(1)	12,312		20,456
Total income from operations	$	50,352	$	14,424

_______________________________________________

(1)The three months ended October 31, 2019 includes acquisition-related charges incurred in connection with the Hu-Friedy acquisition.